NZ609712A - Biomarkers for predicting the efficacy of an immunotherapy against cancer - Google Patents
Biomarkers for predicting the efficacy of an immunotherapy against cancerInfo
- Publication number
- NZ609712A NZ609712A NZ609712A NZ60971211A NZ609712A NZ 609712 A NZ609712 A NZ 609712A NZ 609712 A NZ609712 A NZ 609712A NZ 60971211 A NZ60971211 A NZ 60971211A NZ 609712 A NZ609712 A NZ 609712A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- group
- immunotherapy
- cancer patient
- marker
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 10
- 201000011510 cancer Diseases 0.000 title abstract 8
- 238000009169 immunotherapy Methods 0.000 title abstract 5
- 239000000090 biomarker Substances 0.000 title 1
- 230000009286 beneficial effect Effects 0.000 abstract 3
- 210000004369 blood Anatomy 0.000 abstract 3
- 239000008280 blood Substances 0.000 abstract 3
- 238000003018 immunoassay Methods 0.000 abstract 3
- 239000003550 marker Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 abstract 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 abstract 2
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 2
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 2
- 206010017758 gastric cancer Diseases 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000000523 sample Substances 0.000 abstract 2
- 201000011549 stomach cancer Diseases 0.000 abstract 2
- 230000004083 survival effect Effects 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- 238000002965 ELISA Methods 0.000 abstract 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000011324 bead Substances 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000007419 epigenetic assay Methods 0.000 abstract 1
- 238000010195 expression analysis Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000012520 frozen sample Substances 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 210000003563 lymphoid tissue Anatomy 0.000 abstract 1
- 238000004949 mass spectrometry Methods 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000002493 microarray Methods 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41698110P | 2010-11-24 | 2010-11-24 | |
| GBGB1021289.2A GB201021289D0 (en) | 2010-12-15 | 2010-12-15 | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| US42365210P | 2010-12-16 | 2010-12-16 | |
| PCT/EP2011/070661 WO2012069462A1 (en) | 2010-11-24 | 2011-11-22 | Biomarkers for predicting the efficacy of an immunotherapy against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ609712A true NZ609712A (en) | 2015-05-29 |
Family
ID=43567254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ609712A NZ609712A (en) | 2010-11-24 | 2011-11-22 | Biomarkers for predicting the efficacy of an immunotherapy against cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8669063B2 (enExample) |
| EP (1) | EP2643698B1 (enExample) |
| JP (1) | JP6005051B2 (enExample) |
| KR (1) | KR20130119453A (enExample) |
| CN (1) | CN103384827B (enExample) |
| AU (1) | AU2011333819A1 (enExample) |
| BR (1) | BR112013012820A2 (enExample) |
| CA (1) | CA2818738A1 (enExample) |
| EA (1) | EA201390762A1 (enExample) |
| ES (1) | ES2592957T3 (enExample) |
| GB (1) | GB201021289D0 (enExample) |
| HU (1) | HUE030005T2 (enExample) |
| MX (1) | MX341734B (enExample) |
| NZ (1) | NZ609712A (enExample) |
| PL (1) | PL2643698T3 (enExample) |
| SG (1) | SG190698A1 (enExample) |
| WO (1) | WO2012069462A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US9026531B2 (en) * | 2012-04-17 | 2015-05-05 | Cerner Innovation, Inc. | Associating multiple data sources into a web-accessible framework |
| EP2864792A1 (en) | 2012-06-26 | 2015-04-29 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| CN103048453B (zh) * | 2012-12-18 | 2014-11-26 | 苏州浩欧博生物医药有限公司 | 一种糖类抗原ca19-9的纳米磁微粒化学发光测定试剂盒及其制备方法和检测方法 |
| RU2677742C2 (ru) | 2013-11-07 | 2019-01-21 | Медиал Рисеч Лтд. | Способы и системы оценки риска развития злокачественной опухоли легкого |
| EP2942629A1 (en) * | 2014-05-08 | 2015-11-11 | Universität Würzburg | Predictive markers for successful cancer immunotherapy |
| GB201505585D0 (en) * | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| WO2017008046A1 (en) * | 2015-07-08 | 2017-01-12 | Children's Hospital Medical Center | Loss of transcriptional fidelity leads to immunotherapy resistance in cancers |
| CN112710723B (zh) * | 2015-07-13 | 2024-11-12 | 佰欧迪塞克斯公司 | 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法 |
| CN108601731A (zh) | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
| WO2017136139A1 (en) | 2016-02-01 | 2017-08-10 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy |
| CN105624110A (zh) * | 2016-02-29 | 2016-06-01 | 时宏珍 | Hla-a0201限制性抗psa抗原特异性ctl的制备方法 |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| CN109690314B (zh) * | 2016-05-09 | 2022-08-02 | 法国国家卫生及研究医学协会 | 患有实体癌症的患者的分类方法 |
| US20190177430A1 (en) * | 2016-08-24 | 2019-06-13 | The Wistar Institute Of Anatomy And Biology | Methods of Treating Cancers With Chemotherapy With Reduced Toxicity |
| CN106198987A (zh) * | 2016-08-31 | 2016-12-07 | 辽宁迈迪生物科技股份有限公司 | 一种用于评价肿瘤免疫细胞疗法的检测标记物及其检测方法和应用 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| EP3566054A4 (en) * | 2017-01-05 | 2020-12-09 | Biodesix, Inc. | PROCESS FOR IDENTIFYING CANCER PATIENTS LIKELY TO BENEFIT FROM IMMUNOTHERAPY FOR LASTING SUSTAINABLE SUB-GROUPS OF PATIENTS WHO HAVE A BAD PROGNOSIS GENERALLY |
| US10699007B2 (en) * | 2017-03-13 | 2020-06-30 | Oracle International Corporation | Hybrid univariate/multivariate prognostic-surveillance technique |
| WO2018221820A1 (ko) * | 2017-06-02 | 2018-12-06 | 이종균 | 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트 |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| EP3773691A4 (en) | 2018-03-29 | 2022-06-15 | Biodesix, Inc. | Apparatus and method for identification of primary immune resistance in cancer patients |
| US20210263045A1 (en) * | 2018-04-06 | 2021-08-26 | The Board Of Regents Of The University Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
| CN108624650B (zh) * | 2018-05-14 | 2022-04-29 | 乐普（北京）医疗器械股份有限公司 | 判断实体瘤是否适合免疫治疗的方法和检测试剂盒 |
| CN110885886B (zh) * | 2018-09-07 | 2023-04-07 | 华中科技大学同济医学院附属协和医院 | 一种胶质母细胞瘤鉴别诊断及胶质瘤生存预后的分型方法 |
| KR102159538B1 (ko) * | 2019-01-11 | 2020-09-24 | 충남대학교 산학협력단 | 폐암 환자의 면역항암제에 대한 치료 반응성 예측용 il-6 마커 및 이의 용도 |
| EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
| CN113614537B (zh) * | 2019-03-28 | 2025-10-17 | 豪夫迈·罗氏有限公司 | 癌症预后 |
| CN111257563B (zh) * | 2020-01-22 | 2022-08-23 | 广州泛恩生物科技有限公司 | Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途 |
| EP4168802A4 (en) * | 2020-06-21 | 2025-03-19 | Oncohost Ltd | HOST SIGNATURES THAT PREDICTE IMMUNOTHERAPY RESPONSE |
| WO2022006514A1 (en) * | 2020-07-02 | 2022-01-06 | Gopath Laboratories Llc | Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer |
| US20230266337A1 (en) * | 2020-07-10 | 2023-08-24 | Sekisui Medical Co., Ltd. | Composition containing tarc, and method for improving storage stability of tarc |
| CN113219173A (zh) * | 2021-05-11 | 2021-08-06 | 中南大学湘雅医院 | Sh2b1在肺癌诊断中的应用 |
| CN113462776B (zh) * | 2021-06-25 | 2023-03-28 | 复旦大学附属肿瘤医院 | m6A修饰相关联合基因组在预测肾透明细胞癌患者免疫治疗疗效中的应用 |
| CN115058440B (zh) * | 2022-06-08 | 2023-08-15 | 郑州轻工业大学 | 催化合成天然蔗糖酯的工程菌及其构建方法和应用 |
| CN115612737A (zh) * | 2022-08-03 | 2023-01-17 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 一种胃癌免疫治疗疗效预测和预后评估的方法及其应用 |
| CN118072954A (zh) * | 2024-02-06 | 2024-05-24 | 江南大学附属医院 | 一种基于trp评分系统的胃癌免疫治疗反应预测方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| JP3490893B2 (ja) * | 1998-06-02 | 2004-01-26 | 富士レビオ株式会社 | 胃癌の診断方法 |
| WO2005098446A2 (en) * | 2004-03-31 | 2005-10-20 | The Johns Hopkins University | Biomarkers for ovarian cancer |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| BRPI0618564A2 (pt) * | 2005-11-02 | 2011-09-06 | Bayer Healthcare Llc | métodos para predição e prognóstico de cáncer e para monitoração de terapia contra cáncer |
| US20090035801A1 (en) * | 2005-12-27 | 2009-02-05 | Power3 Medical Products, Inc. | Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer |
| WO2007127749A2 (en) * | 2006-04-24 | 2007-11-08 | Critical Care Diagnostics, Inc. | Predicting mortality and detecting severe disease |
| AT504231A1 (de) * | 2006-10-03 | 2008-04-15 | Hans Dr Loibner | Prädiktive parameter |
| WO2009015841A1 (en) * | 2007-07-27 | 2009-02-05 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| EP2080812A1 (en) * | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| EP2105740A1 (en) * | 2008-03-28 | 2009-09-30 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Biomarkers for monitoring or predicting the treatment of cancer |
| RU2011101378A (ru) | 2008-06-16 | 2012-07-27 | Сайвидон Дайагностикс Гмбх (De) | Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии |
| WO2010076322A1 (en) | 2008-12-30 | 2010-07-08 | Siemens Healthcare Diagnostics Inc. | Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer |
| US20100240546A1 (en) * | 2009-03-20 | 2010-09-23 | Samuel Chun Lap Lo | Use of biomarkers for the diagnosis and prognosis of lung cancer |
-
2010
- 2010-12-15 GB GBGB1021289.2A patent/GB201021289D0/en not_active Ceased
-
2011
- 2011-11-22 US US13/302,674 patent/US8669063B2/en active Active
- 2011-11-22 ES ES11788121.9T patent/ES2592957T3/es active Active
- 2011-11-22 KR KR1020137015847A patent/KR20130119453A/ko not_active Ceased
- 2011-11-22 JP JP2013540324A patent/JP6005051B2/ja not_active Expired - Fee Related
- 2011-11-22 HU HUE11788121A patent/HUE030005T2/en unknown
- 2011-11-22 SG SG2013035530A patent/SG190698A1/en unknown
- 2011-11-22 NZ NZ609712A patent/NZ609712A/en not_active IP Right Cessation
- 2011-11-22 WO PCT/EP2011/070661 patent/WO2012069462A1/en not_active Ceased
- 2011-11-22 MX MX2013005762A patent/MX341734B/es active IP Right Grant
- 2011-11-22 PL PL11788121.9T patent/PL2643698T3/pl unknown
- 2011-11-22 CA CA2818738A patent/CA2818738A1/en not_active Abandoned
- 2011-11-22 BR BR112013012820A patent/BR112013012820A2/pt active Search and Examination
- 2011-11-22 EP EP11788121.9A patent/EP2643698B1/en active Active
- 2011-11-22 AU AU2011333819A patent/AU2011333819A1/en not_active Abandoned
- 2011-11-22 EA EA201390762A patent/EA201390762A1/ru unknown
- 2011-11-22 CN CN201180056555.2A patent/CN103384827B/zh not_active Expired - Fee Related
-
2014
- 2014-01-17 US US14/158,054 patent/US9389235B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HUE030005T2 (en) | 2017-04-28 |
| JP2014500493A (ja) | 2014-01-09 |
| SG190698A1 (en) | 2013-07-31 |
| GB201021289D0 (en) | 2011-01-26 |
| US9389235B2 (en) | 2016-07-12 |
| US20120128702A1 (en) | 2012-05-24 |
| ES2592957T3 (es) | 2016-12-02 |
| CN103384827B (zh) | 2016-06-08 |
| BR112013012820A2 (pt) | 2017-05-09 |
| PL2643698T3 (pl) | 2016-12-30 |
| AU2011333819A1 (en) | 2013-05-23 |
| CA2818738A1 (en) | 2012-05-31 |
| KR20130119453A (ko) | 2013-10-31 |
| EA201390762A1 (ru) | 2013-09-30 |
| WO2012069462A1 (en) | 2012-05-31 |
| EP2643698A1 (en) | 2013-10-02 |
| CN103384827A (zh) | 2013-11-06 |
| US20140234347A1 (en) | 2014-08-21 |
| EP2643698B1 (en) | 2016-06-22 |
| MX341734B (es) | 2016-08-31 |
| US8669063B2 (en) | 2014-03-11 |
| MX2013005762A (es) | 2013-08-12 |
| JP6005051B2 (ja) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ609712A (en) | Biomarkers for predicting the efficacy of an immunotherapy against cancer | |
| Broggi et al. | Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients | |
| Li et al. | Exosomal proteins as potential markers of tumor diagnosis | |
| Saraon et al. | Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer | |
| Nawaz et al. | Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery | |
| Huang et al. | Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients | |
| Mocan et al. | Liquid biopsies in hepatocellular carcinoma: are we winning? | |
| Boersema et al. | Quantification of the N-glycosylated secretome by super-SILAC during breast cancer progression and in human blood samples | |
| Shah et al. | Biomarkers for early detection of colorectal cancer and polyps: systematic review | |
| Zhang et al. | Diagnosis value of serum B7-H3 expression in non-small cell lung cancer | |
| WO2011119934A3 (en) | Methods and materials for detecting colorectal neoplasm | |
| Zhang et al. | Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer | |
| Roe et al. | Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study | |
| CN106164289A (zh) | 癌症对免疫疗法的反应的决定因素 | |
| JP2014500493A5 (enExample) | ||
| JP2022037137A (ja) | 原発性胃腺癌の体細胞プロモーター特性を明らかにするエピゲノムプロファイリング | |
| Lee et al. | Overexpressed tryptophanyl-tRNA synthetase, an angiostatic protein, enhances oral cancer cell invasiveness | |
| Müller et al. | Global analysis of glycoproteins identifies markers of endotoxin tolerant monocytes and GPR84 as a modulator of TNFα expression | |
| Steinbach et al. | ERAP1 overexpression in HPV-induced malignancies: a possible novel immune evasion mechanism | |
| Sasaroli et al. | Beyond CA125: the coming of age of ovarian cancer biomarkers | |
| Jiang et al. | Aberrant expression of Golgi protein 73 is indicative of a poor outcome in hepatocellular carcinoma | |
| Rao et al. | Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer | |
| Huang et al. | Application of extracellular vesicles proteins in cancer diagnosis | |
| Liu et al. | Expression of GOLPH2 is associated with the progression of and poor prognosis in gastric cancer | |
| He et al. | Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 NOV 2016 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20151224 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 NOV 2017 BY PAVIS GMBH Effective date: 20161110 |
|
| LAPS | Patent lapsed |